Q1 2023
Released May 11, 2023, before the open
10-Q filed May 11, 2023, 41 days after period end · 0001628280-23-017423
Q1 2023 · 10-Q
Revenue$0.00$0.00 no prior Q1 2022 on fileno prior Q4 2022 on file
Net Income-$39.40M-$39.40M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.44-$0.44 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$40,033,000N/M
Operating Cash Flow-$41,561,000N/M
Free Cash Flowderived-$43,560,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|
| Revenue | $0.00 | — | — |
| Net Income | -$39.40M | -$23.84M | -$86.66M |
| EPS Diluted | -$0.44 | -$1.58 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR